Ozmosi | Aminolaevulinic acid Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Aminolaevulinic acid

Pronounced as: uh-MEE-noh-LEE-vyoo-LIN-ik AS-id

Alternative Names: Aminolaevulinic acid
Clinical Status: Active
Latest Update: 2026-02-10
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action:

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Company Location: Asia Pacific
Company Founding Year: 1996
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Aminolaevulinic acid

Countries in Clinic: China

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Carcinoma in Situ|Cervical Cancer|Cervical Intraepithelial Neoplasia|Communicable Diseases|Papillomavirus Infections|Uterine Cervical Diseases|Uterine Cervical Dysplasia|Uterine Diseases

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT06439433

FDZJYX-ALA-202001

P2

Completed

Uterine Cervical Diseases|Uterine Diseases|Carcinoma in Situ|Cervical Intraepithelial Neoplasia|Uterine Cervical Dysplasia|Communicable Diseases|Cervical Cancer|Papillomavirus Infections

2023-12-20

2024-06-04

Primary Endpoints|Treatments